MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

5.268 -0.232 (-4.21%)
Streaming Delayed Price Updated: 9:47 AM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 211,557
Open 5.400
Bid (Size) 5.250 (2,300)
Ask (Size) 5.270 (500)
Prev. Close 5.500
Today's Range 5.260 - 5.460
52wk Range 4.910 - 14.00
Shares Outstanding 95,568,307
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire

Performance

YTD
-54.1%
-54.1%
1 Month
-11.3%
-11.3%
3 Month
-35.5%
-35.5%
6 Month
-42.8%
-42.8%
1 Year
-61.0%
-61.0%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY): Bloom Energy Corporation (NYSE: BE); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Via Benzinga
Topics Earnings
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
Via Newsfile
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
From DJS LAW GROUP
Via Business Wire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
The current price of ARS Pharmaceuticals, Inc. - Common Stock is 5.268
When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 08/24/26 09:47 AM ET
What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 503.49M
How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
ARS Pharmaceuticals, Inc. - Common Stock has 503M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story